Stibbe advises Lundbeck

Matter
NL Law

Stibbe advised Lundbeck on the acquisition of Prexton Therapeutics BV for an amount of up to EUR 905 million.

Lundbeck (listed on the Copenhagen Stock Exchange in Denmark) is a global pharmaceutical company specialising in psychiatric and neurological disorders with a focus on Alzheimer's disease, depression, Parkinson's disease and schizophrenia.